topotecan and cyclophosphamide in adults with relapsed sarcoma与复发肉瘤topotecan和环磷酰胺在成人.pdfVIP

Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 749067, 4 pages doi:10.1155/2012/749067 Research Article Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma P. Blanchette,1 D. Hogg,2 P. Ferguson,3 J. S. Wunder,3 C. Swallow,4 R. Gladdy,4 P. Chung,5 B. O’Sullivan,5 M. E. Blackstein,2 C. Catton,5 and A. A. Gupta2 1 Department of Internal Medicine, University of Toronto, Toronto, Canada 2 Department of Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Canada 3 University Musculoskeletal Oncology Unit, Division of Orthopaedic Surgery, Mount Sinai Hospital, University of Toronto, Canada 4 Division of General Surgery, Mount Sinai Hospital, University of Toronto, Canada 5 Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Canada Correspondence should be addressed to A. A. Gupta, abha.gupta@sickkids.ca Received 1 May 2012; Accepted 1 June 2012 Academic Editor: Luca Sangiorgi Copyright © 2012 P. Blanchette et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. The combination of topotecan and cyclophosphamide (TC) has activity in pediatric patients with recurrent sarcoma, especially Ewing’s sarcoma (EWS). We sought to determine the toxicity of and response to TC in adults with recurrent sarcoma. 2 Patients and Methods. Adults treated with TC from 2005 to 2010 were reviewed who received T = topotecan at 0.75 mg/m /day (days